Uncategorised - European Medical Journal

COMy 2025: Infection Risk High with Bispecific Antibodies in Myeloma

New research from COMy 2025 reveals a high rate of infections among people with relapsed or refractory multiple myeloma receiving bispecific antibodies…

Exercise May Help Close Survival Gap in Colon Cancer

Research shows that regular physical activity can help close the survival gap for stage III colon cancer, with those who exercise achieving survival rates similar to the general population.

Precision Approaches in Colorectal Cancer: Interview with John Strickler

It has been known for years that there is a small subgroup of patients with colorectal cancer who have HER2-positive disease…

Global Diarrhoeal Deaths Drop, But Burden Persists

This dramatic decline highlights the success of interventions such as oral rehydration therapy, rotavirus vaccination, and improvements in water and sanitation.

UTI Turns Out to Be Infective Endocarditis: An Unusual Presentation

Infective endocarditis (IE) often presents in an unusual and vague manner, especially in its early stages, where symptoms can be…

COMy 2025: Senescence Biomarkers Predict Frailty and Survival in Myeloma

New research, from COMy 2025, has found that specific senescence-associated biomarkers are significantly correlated with frailty and overall survival in newly diagnosed multiple myeloma.

Skin Bacteria Shape Immune Response to UV Light

Interestingly, UVB exposure and topical application of cis-UCA led to changes in the skin’s microbial composition.

EuroPCR 2025: Routine Embolic Protection Not Effective for Stroke Prevention in TAVI

Largest meta-analysis shows no reduction in stroke with routine cerebral embolic protection during TAVI procedures.

Inside the Cancer Vaccine Revolution: Interview with Lennard Lee

I’m a clinical academic, which is quite a rare breed of doctor, because what I’m doing, along with other clinical academics, is being…

The Evolving Standard of Care in Advanced Biliary Tract Cancers

This infographic presents three-year follow-up data from the TOPAZ-1 trial; the first global Phase III study to evaluate an immuno…